These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20526289)

  • 1. An unhealthy disregard.
    Nat Med; 2010 Jun; 16(6):609. PubMed ID: 20526289
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting drug companies' bottom line.
    Prescrire Int; 2011 Jan; 20(112):25. PubMed ID: 21462792
    [No Abstract]   [Full Text] [Related]  

  • 3. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD; Levy MC; Schwab GG; Paik Y
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract]   [Full Text] [Related]  

  • 4. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J
    Seton Hall Law Rev; 2013; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract]   [Full Text] [Related]  

  • 5. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A; Carome MA
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 7. Off-label prescription advertising, the FDA and the First Amendment: a study in the values of commercial speech protection.
    Klasmeier C; Redish MH
    Am J Law Med; 2011; 37(2-3):315-57. PubMed ID: 21847884
    [No Abstract]   [Full Text] [Related]  

  • 8. Hidden truth: The perils and protection of off-label drug and medical device promotion.
    Conko G
    Health Matrix Clevel; 2011; 21(1):149-87. PubMed ID: 21847900
    [No Abstract]   [Full Text] [Related]  

  • 9. Off-label marketing and the First Amendment.
    Boumil MM
    N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 11. Off-label marketing: free speech or illegal promotion?
    Silverman E
    BMJ; 2013 Jan; 346():f320. PubMed ID: 23341546
    [No Abstract]   [Full Text] [Related]  

  • 12. GlaxoSmithKline is fined record $3bn in US.
    Roehr B
    BMJ; 2012 Jul; 345():e4568. PubMed ID: 22761252
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug risks and free speech--can Congress ban consumer drug ads?
    Shuchman M
    N Engl J Med; 2007 May; 356(22):2236-9. PubMed ID: 17476002
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 15. Major issues in marketing regulation.
    Pines WL
    Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
    [No Abstract]   [Full Text] [Related]  

  • 16. Understanding government regulation of the marketing and advertising of medical devices, drugs, and biologics: the challenges of the Internet.
    Reichertz PS
    Food Drug Law J; 1997; 52(3):303-8. PubMed ID: 10343029
    [No Abstract]   [Full Text] [Related]  

  • 17. Off-Label Marketing's Audiences: The 21
    Halabi SF
    Am J Law Med; 2018 May; 44(2-3):181-196. PubMed ID: 30106659
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary: can we talk? About Food and Drug Regulation and the First Amendment.
    Cohen MN
    Food Drug Law J; 2003; 58(4):741-56. PubMed ID: 15027458
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: FDA oversight.
    ; Berry MD
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.